Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Prader-Willi Syndrome
Interventions
DRUG

DCCR

Once daily oral administration

Trial Locations (22)

11501

NYU Winthrop Hospital, Mineola

20892

National Institutes of Health, Bethesda

30329

Emory Children's Center, Atlanta

32608

U of Florida Gainesville, Gainesville

37212

Vanderbilt University, Nashville

43205

The Research Institute at Nationwide Children's Hospital, Columbus

46202

Indiana University School of Medicine, Indianapolis

48912

Sparrow Clinical Research Institute, Lansing

55102

Children's Hospital and Clinic Minnesota, Saint Paul

75231

Research Institute of Dallas, Dallas

84112

University of Utah, Salt Lake City

92123

Rady Children's Hospital of San Diego, San Diego

92868

UC Irvine, Orange

94304

Stanford University, Palo Alto

98105

Seattle Children's, Seattle

02115

Boston Children's Hospital, Boston

07503

St. Joseph's University Medical Center, Paterson

CB21 5EF

Fulbourn Hospital, Cambridge

G51 4TF

The Queen Elizabeth University, Glasgow

HU3 2JZ

Hull and East Yorkshire Hospitals NHS Trust, Hull

E1 1BB

Royal London Hospital, London

SW10 9NH

Chelsea and Westminster Hospital, London

All Listed Sponsors
lead

Soleno Therapeutics, Inc.

INDUSTRY